Cibus (CBUS) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cibus (CBUS) has outperformed Tenaya Therapeutics (TNYA) over the past year, gaining 8.2% versus a loss of 69.9%. Over five years, TNYA leads with a -97.4% price change compared with -98.9% for CBUS. Tenaya Therapeutics is the larger company by market cap ($122.0 million vs $121.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBUS | TNYA |
|---|---|---|
| Share price | $1.59 | $0.5442 |
| Market cap | $121.52M | $122.03M |
| 1-day change | -1.85% | +2.02% |
| YTD return | -8.62% | -25.08% |
| 1-year return | +8.16% | -69.86% |
| 5-year return | -98.92% | -97.41% |
| EPS (TTM) | $-1.62 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $2.35 |
| 52-week low | $1.09 | $0.5211 |
| Distance from 52-week high | -62.06% | -76.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +801.26% | +488.02% |
| Average volume | 195.29K | 2.26M |
| Shares outstanding | 76.43M | 224.23M |
| Employees | 118 | 70 |
| Sector | Industrials | Health Care |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBUS has outperformed TNYA by 78.0 percentage points over the past year.
- The two companies sit in different sectors: Cibus in Industrials and Tenaya Therapeutics in Health Care.
About Cibus
CBUS stock →Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits.
Industrials · Agricultural Chemicals · 118 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
CBUS vs TNYA FAQ
Which is bigger, Cibus or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $122.03M compared with $121.52M for Cibus (CBUS).
Which stock has performed better over the past year, CBUS or TNYA?
CBUS returned +8.16% over the past 12 months, compared with -69.86% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Cibus and Tenaya Therapeutics in the same industry?
No. Cibus is in the Industrials sector, while Tenaya Therapeutics is in Health Care.